6-fluoro-3-tyrosine has been researched along with Disease Exacerbation in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bendlin, BB; Buyan-Dent, L; Christian, BT; DeJesus, OT; Gallagher, CL; Harding, SJ; Holden, JE; Li, CT; Nickles, RJ; Oh, J; Okonkwo, O; Palotti, M; Stone, CK | 1 |
| Bankiewicz, KS; Eberling, JL; Jagust, WJ; Jordan, S; VanBrocklin, HF | 1 |
2 other study(ies) available for 6-fluoro-3-tyrosine and Disease Exacerbation
| Article | Year |
|---|---|
A dual-tracer study of extrastriatal 6-[18F]fluoro-m-tyrosine and 6-[18F]-fluoro-L-dopa uptake in Parkinson's disease.
Topics: Brain; Dihydroxyphenylalanine; Disease Progression; Female; Fluorine Radioisotopes; Humans; Image Processing, Computer-Assisted; Levodopa; Magnetic Resonance Imaging; Male; Middle Aged; Parkinson Disease; Positron-Emission Tomography; Radiopharmaceuticals; Time Factors; Tyrosine | 2014 |
PET studies of functional compensation in a primate model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Corpus Striatum; Disease Progression; Dopamine Agents; Fluorine Radioisotopes; Macaca mulatta; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Neurotoxins; Pargyline; Parkinson Disease, Secondary; Tomography, Emission-Computed; Tyrosine | 1997 |